Rhumbline Advisers Clearside Biomedical, Inc. Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.97 - $1.48 $1,059 - $1,616	1,092 New	1,092 $1,000
Q2 2019 Aug 14, 2019	SELL	$0.97 - $1.42 $35,219 - $51,558	-36,309 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$1.1 - $1.74 $737 - $1,165	-670 Reduced 1.81%	36,309 $50,000
Q4 2018 Jan 31, 2019	BUY	$1.0 - $6.12 $12,076 - $73,905	12,076 Added 48.49%	36,979 $40,000
Q3 2018 Nov 07, 2018	SELL	$6.03 - $11.24 $10,854 - $20,232	-1,800 Reduced 6.74%	24,903 $153,000
Q2 2018 Aug 06, 2018	BUY	$8.91 - $14.54 $71,787 - $117,148	8,057 Added 43.21%	26,703 $285,000
Q1 2018 May 02, 2018	BUY	$5.57 - $14.28 $5,514 - $14,137	990 Added 5.61%	18,646 $200,000
Q4 2017 Feb 09, 2018	SELL	$5.78 - $9.12 $24,073 - $37,984	-4,165 Reduced 19.09%	17,656 $124,000
Q3 2017 Nov 06, 2017	BUY	$6.73 - $8.74 $146,855 - $190,715	21,821	21,821 $191,000

12.1M

54.7K

50.7K

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $59M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.